Valerie Deroo | Global Value Access, Public Policy and Government Affairs Lead -Rare Disease
ITALFARMACO S.P.A.

Day 3 - Friday 25th October @ 10:40

Challenges for defining value in Rare Diseases: the case for Duchenne Muscular Dystrophy (DMD)

Successful development of new treatments for rare diseases and their patient access require overcoming a series of challenges when defining value during the health technology assessment (HTA). 

As potential new treatments for Duchenne Muscular Dystrophy near the market, understanding the factors that influence society’s willingness and ability to pay for these treatments will be central for assessing their value. Traditional assessment focusing on cost-effectiveness or budget impact would need to evolve to consider broader elements of value to enable a more holistic approach to value innovation.

Valerie Deroo, Global Value Access, Public Policy and Government Affairs Lead -Rare Disease, ITALFARMACO S.P.A.

×

Valerie Deroo / Challenges for defining value in Rare Diseases: the case for Duchenne Muscular Dystrophy (DMD)

Valerie Deroo, Global Value Access, Public Policy and Government Affairs Lead -Rare Disease,
ITALFARMACO S.P.A.

Valérie is the Head of Value & Access and Government Affairs for Rare Diseases, at the Italfarmaco Group since March 2023. She is leading the Italfamarco Rare Diseases Value & Access organization, bringing together years of experience, dedication, innovation and curiosity, striving to...

CloseMore